| Identification | Back Directory | [Name]
ARRY382 | [CAS]
1313407-95-2 | [Synonyms]
ARRY382 RRY-382 ARRY-382 ARRY 382,ARRY382 N-(3-cyclopropyl-1-((6-methylpyridin-2-yl)methyl)-1H-indazol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)imidazo[1,2-a]pyridine-3-carboxamide Imidazo[1,2-a]pyridine-3-carboxamide, N-[3-cyclopropyl-1-[(6-methyl-2-pyridinyl)methyl]-1H-indazol-4-yl]-7-[2-(4-methyl-1-piperazinyl)ethoxy]- | [Molecular Formula]
C32H36N8O2 | [MDL Number]
MFCD32709977 | [MOL File]
1313407-95-2.mol | [Molecular Weight]
564.68 |
| Hazard Information | Back Directory | [Uses]
ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers[1]. | [References]
[1] David K Edwards V, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 2018 May 15;9(37):24576-24589. DOI:10.18632/oncotarget.25191 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|